Eucommia bark extract treated fatty liver disease in mice by promoting butyrate-producing gut bacteria, which stimulated the body's own GLP-1 production and activated liver fat-burning pathways.
FMT reproduced all benefitsFecal microbiota transplantation from Eucommia-treated donors to untreated mice recapitulated the metabolic improvements, proving the gut microbiome is the key mediator
What the researchers found
Eucommia bark extract (EBE) dramatically attenuated high-fat-diet-induced weight gain, oxidative stress, inflammation, lipid accumulation, and liver fibrosis in MASLD mice. The complete mechanistic chain was mapped:
1. EBE selectively expanded Faecalibacterium prausnitzii (a major butyrate-producing bacterium) in the gut
2. This increased colonic butyric acid levels
3. Butyrate activated GPR43 receptors on enteroendocrine cells (confirmed by GPR43 knockdown abolishing the response)
4. GPR43 activation drove GLP-1 synthesis, raising circulating GLP-1 levels
5. GLP-1 enhanced AMPK phosphorylation in the liver via GLP-1 receptor signaling
6. Activated AMPK suppressed lipogenesis (fat creation) and promoted lipophagy (fat breakdown)
Critically, EBE did not directly trigger GLP-1 release in STC-1 cells in vitro — the effect was entirely microbiome-mediated. Fecal microbiota transplantation from EBE-treated donors recapitulated all metabolic improvements in recipient mice.
Why it matters
MASLD is the most common chronic liver disease worldwide with no truly effective drug treatments. This study reveals a natural way to boost the body's own GLP-1 production through gut microbiome modification — essentially achieving some of the metabolic benefits of GLP-1 drugs (like semaglutide) by stimulating the body to make more of its own GLP-1. The fecal transplant confirmation is particularly compelling, proving the gut bacteria are the key mediators.
How the study worked
C57BL/6 mice were fed a high-fat diet to induce MASLD and orally administered Eucommia bark extract throughout feeding. Metabolic parameters, liver histology, and signaling pathways were assessed. Gut microbiota composition was analyzed by 16S rRNA sequencing. In vitro experiments tested whether EBE directly stimulated GLP-1 release in STC-1 enteroendocrine cells. GPR43 knockdown confirmed the receptor's role. Fecal microbiota transplantation from EBE-treated donors to recipient mice tested whether the gut microbiome changes were sufficient to reproduce benefits.
What this study cannot tell us
This is a mouse study, and the high-fat diet model may not fully replicate human MASLD. The Eucommia bark extract is a complex mixture of many compounds, and the specific active components driving the microbiome changes are not identified. Quantitative data on the degree of GLP-1 increase, weight loss, and liver improvement are not specified in the abstract. Human gut microbiome responses to the same extract may differ significantly. Long-term safety and the durability of microbiome changes after stopping treatment are unknown.
How to read the evidence
This is a preclinical animal study with in vitro mechanistic validation and fecal microbiota transplantation confirmation. The multi-level evidence (in vivo, in vitro, FMT, GPR43 knockdown) provides strong mechanistic support, but no human data exists. The evidence is preclinical but thorough.
When this study was published
Published in 2026, this is very recent research reflecting the current convergence of microbiome science, GLP-1 biology, and metabolic liver disease research.
The bigger picture
This study sits at the intersection of three hot research areas: the gut microbiome, GLP-1 biology, and metabolic liver disease. While GLP-1 receptor agonists like semaglutide are being tested for MASLD treatment, this work suggests an alternative approach — stimulating endogenous GLP-1 production through microbiome manipulation. F. prausnitzii is already one of the most studied 'beneficial' gut bacteria, and butyrate is a well-known driver of gut health. This study connects these established concepts into a complete therapeutic pathway.
Questions still open
- Could Eucommia bark extract or its active components serve as a prebiotic supplement to boost endogenous GLP-1 production in humans with fatty liver disease?
- Would directly supplementing with F. prausnitzii or butyrate achieve the same liver-protective effects without needing the herbal extract?
- How do the GLP-1 levels achieved through this microbiome pathway compare to those from pharmaceutical GLP-1 agonists like semaglutide?
Common questions
How does a gut bacterium end up treating liver disease?
Is this the same GLP-1 that drugs like Ozempic target?
Read the original research
Eucommia alleviates high fat diet-induced MASLD via the F. prausnitzii/butyrate/GPR43/GLP-1 signaling.
Journal of ethnopharmacology, 355(Pt A), 120587
Citation
Wang, Zhineng; Zhu, Ying; Wang, Guohua; Sun, Mayu; Yao, Wenbo; Ba, Qian. (2026). Eucommia alleviates high fat diet-induced MASLD via the F. prausnitzii/butyrate/GPR43/GLP-1 signaling.. Journal of ethnopharmacology, 355(Pt A), 120587. https://doi.org/10.1016/j.jep.2025.120587